These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35983808)

  • 21. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
    Lynn R; Krunic A
    Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S; Lee YB; Choe SJ; Lee WS
    Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Depression Associated With Finasteride Treatment.
    Pompili M; Magistri C; Maddalena S; Mellini C; Persechino S; Baldessarini RJ
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):304-309. PubMed ID: 33814544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs.
    La Torre A; Giupponi G; Duffy D; Conca A; Cai T; Scardigli A
    Pharmacopsychiatry; 2016 Jan; 49(1):3-13. PubMed ID: 26569417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors.
    Coskuner ER; Ozkan B; Culha MG
    Sex Med Rev; 2019 Apr; 7(2):277-282. PubMed ID: 30301703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical post-finasteride syndrome: A pharmacological riddle.
    Gupta AK; Sharma N; Shukla P
    Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.
    Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B
    World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finasteride for hair loss: a review.
    Gupta AK; Venkataraman M; Talukder M; Bamimore MA
    J Dermatolog Treat; 2022 Jun; 33(4):1938-1946. PubMed ID: 34291720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.
    Kaplan SA; Lee JY; Meehan AG; Kusek JW
    J Urol; 2016 Jun; 195(6):1825-9. PubMed ID: 26678956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations of gut microbiota composition in post-finasteride patients: a pilot study.
    Borgo F; Macandog AD; Diviccaro S; Falvo E; Giatti S; Cavaletti G; Melcangi RC
    J Endocrinol Invest; 2021 Jun; 44(6):1263-1273. PubMed ID: 32951160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.
    Traish AM; Hassani J; Guay AT; Zitzmann M; Hansen ML
    J Sex Med; 2011 Mar; 8(3):872-84. PubMed ID: 21176115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
    Seale LR; Eglini AN; McMichael AJ
    J Drugs Dermatol; 2016 Apr; 15(4):414-9. PubMed ID: 27050696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-finasteride syndrome.
    Pereira AFJR; Coelho TOA
    An Bras Dermatol; 2020; 95(3):271-277. PubMed ID: 32317131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

  • 37. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.
    Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G
    J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Alpha reductase inhibitor related litigation: A legal database review.
    Low P; Li KD; Hakam N; Bell A; Abbasi B; Lui J; Shaw NM; Breyer BN
    Andrology; 2022 Mar; 10(3):470-476. PubMed ID: 34933409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia?
    Motofei IG; Rowland DL; Georgescu SR; Tampa M; Baleanu BC; Paunica S
    Exp Dermatol; 2016 Jul; 25(7):557-8. PubMed ID: 26990657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate, baldness drugs linked to sexual dysfunction.
    Kuehn BM
    JAMA; 2012 May; 307(18):1903. PubMed ID: 22570451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.